HRP20241454T1 - Migalastat za upotrebu u postupcima liječenja fabrijeve bolesti kod pacijenata koji imaju mutaciju u gla genu - Google Patents
Migalastat za upotrebu u postupcima liječenja fabrijeve bolesti kod pacijenata koji imaju mutaciju u gla genu Download PDFInfo
- Publication number
- HRP20241454T1 HRP20241454T1 HRP20241454TT HRP20241454T HRP20241454T1 HR P20241454 T1 HRP20241454 T1 HR P20241454T1 HR P20241454T T HRP20241454T T HR P20241454TT HR P20241454 T HRP20241454 T HR P20241454T HR P20241454 T1 HRP20241454 T1 HR P20241454T1
- Authority
- HR
- Croatia
- Prior art keywords
- migalastat
- salt
- use according
- patient
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719962P | 2018-08-20 | 2018-08-20 | |
| PCT/US2019/013761 WO2020040806A1 (en) | 2018-08-20 | 2019-01-16 | Methods of treating fabry disease in patients having a mutation in the gla gene |
| EP19703514.0A EP3840753B1 (en) | 2018-08-20 | 2019-01-16 | Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241454T1 true HRP20241454T1 (hr) | 2024-12-20 |
Family
ID=65279726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241454TT HRP20241454T1 (hr) | 2018-08-20 | 2019-01-16 | Migalastat za upotrebu u postupcima liječenja fabrijeve bolesti kod pacijenata koji imaju mutaciju u gla genu |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US12594268B2 (enExample) |
| EP (7) | EP3840753B1 (enExample) |
| JP (3) | JP2021535107A (enExample) |
| KR (3) | KR20240017127A (enExample) |
| CN (1) | CN112888439A (enExample) |
| AU (2) | AU2019326252A1 (enExample) |
| BR (1) | BR112021003137A2 (enExample) |
| CA (1) | CA3110065A1 (enExample) |
| CL (3) | CL2021000435A1 (enExample) |
| DK (1) | DK3840753T3 (enExample) |
| EA (1) | EA202190569A1 (enExample) |
| ES (1) | ES2993833T3 (enExample) |
| FI (1) | FI3840753T3 (enExample) |
| HR (1) | HRP20241454T1 (enExample) |
| HU (1) | HUE068783T2 (enExample) |
| IL (2) | IL325185A (enExample) |
| LT (1) | LT3840753T (enExample) |
| MX (2) | MX2021002070A (enExample) |
| PL (1) | PL3840753T3 (enExample) |
| PT (1) | PT3840753T (enExample) |
| RS (1) | RS66094B1 (enExample) |
| SG (1) | SG11202101117QA (enExample) |
| SI (1) | SI3840753T1 (enExample) |
| SM (1) | SMT202400436T1 (enExample) |
| WO (1) | WO2020040806A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2533050T6 (pl) | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| CA3224546C (en) | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| US12594268B2 (en) | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| CN113969313A (zh) * | 2021-11-29 | 2022-01-25 | 百世诺(北京)医学检验实验室有限公司 | 罕见遗传病突变基因及其应用 |
| CN116656704B (zh) * | 2023-06-01 | 2024-11-05 | 华东理工大学 | 用于治疗法布里病的转基因表达盒 |
| CN116622750B (zh) * | 2023-06-01 | 2024-05-31 | 上海勉亦生物科技有限公司 | 优化的人法布里转基因表达盒及其用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| SI2027137T1 (sl) | 2005-06-08 | 2015-06-30 | Amicus Therapeutics, Inc. | Čiščenje imino in amino sladkorja |
| PL2533050T6 (pl) | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| MX2009011473A (es) | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| WO2010048532A1 (en) | 2008-10-24 | 2010-04-29 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| AU2010254092B2 (en) | 2009-05-26 | 2015-11-12 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| US9206457B2 (en) | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| WO2011063048A2 (en) | 2009-11-17 | 2011-05-26 | Baylor Research Institute | Urinary triaosylceramide (gb3) as a marker of cardiac disease |
| SG10201604757RA (en) * | 2011-03-11 | 2016-08-30 | Amicus Therapeutics Inc | Dosing regimens for the treatment of fabry disease |
| US20120283290A1 (en) | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| KR102076585B1 (ko) | 2011-12-22 | 2020-02-12 | 센토제너 아이피 게엠베하 | 리소좀 효소를 재배열하는 능력을 갖는 화합물 및 암브록솔 및/또는 암브록솔의 유도체의 조합물 |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| WO2014014938A1 (en) | 2012-07-17 | 2014-01-23 | Amicus Therapeutics, Inc. | Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation |
| WO2014120900A1 (en) * | 2013-01-31 | 2014-08-07 | Icahn School Of Medicine At Mount Sinai | Enhanced therapeutic regimens for treating fabry disease |
| US20170051267A1 (en) | 2015-08-20 | 2017-02-23 | Research Foundation Of The City University Of New York | Novel alpha-galactosidase a derivatives |
| KR20190087673A (ko) * | 2016-03-22 | 2019-07-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| TW202408513A (zh) | 2016-07-19 | 2024-03-01 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
| US11357834B2 (en) | 2017-01-10 | 2022-06-14 | Amicus Therapeutics, Inc. | Recombinant α-galactosidase A for treatment of Fabry disease |
| CA3224546C (en) | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| SG11202000423XA (en) | 2017-07-19 | 2020-02-27 | Amicus Therapeutics Inc | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| US20200222377A1 (en) | 2017-08-28 | 2020-07-16 | Amicus Therapeutics, Inc. | Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| PT3749308T (pt) | 2018-02-06 | 2024-01-25 | Amicus Therapeutics Inc | Tratamento de pacientes com doença de fabry clássica com migalastato |
| US12594268B2 (en) | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| TW202042812A (zh) * | 2019-01-22 | 2020-12-01 | 美商阿米庫斯醫療股份有限公司 | 減少法布瑞氏症患者中之腦血管事件之方法 |
| MX2021015352A (es) | 2019-06-11 | 2022-04-06 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| KR20220150902A (ko) * | 2020-02-10 | 2022-11-11 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 파브리 질병을 치료하는 방법 |
| AU2021230371A1 (en) * | 2020-03-06 | 2022-09-29 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
-
2019
- 2019-01-16 US US17/269,890 patent/US12594268B2/en active Active
- 2019-01-16 LT LTEPPCT/US2019/013761T patent/LT3840753T/lt unknown
- 2019-01-16 EP EP19703514.0A patent/EP3840753B1/en active Active
- 2019-01-16 KR KR1020247003291A patent/KR20240017127A/ko not_active Ceased
- 2019-01-16 IL IL325185A patent/IL325185A/en unknown
- 2019-01-16 CN CN201980069272.8A patent/CN112888439A/zh active Pending
- 2019-01-16 EP EP23202185.7A patent/EP4299117A3/en active Pending
- 2019-01-16 DK DK19703514.0T patent/DK3840753T3/da active
- 2019-01-16 AU AU2019326252A patent/AU2019326252A1/en not_active Abandoned
- 2019-01-16 EA EA202190569A patent/EA202190569A1/ru unknown
- 2019-01-16 JP JP2021509744A patent/JP2021535107A/ja active Pending
- 2019-01-16 PL PL19703514.0T patent/PL3840753T3/pl unknown
- 2019-01-16 CA CA3110065A patent/CA3110065A1/en active Pending
- 2019-01-16 BR BR112021003137-5A patent/BR112021003137A2/pt unknown
- 2019-01-16 HU HUE19703514A patent/HUE068783T2/hu unknown
- 2019-01-16 FI FIEP19703514.0T patent/FI3840753T3/fi active
- 2019-01-16 KR KR1020247003292A patent/KR20240017128A/ko active Pending
- 2019-01-16 WO PCT/US2019/013761 patent/WO2020040806A1/en not_active Ceased
- 2019-01-16 SM SM20240436T patent/SMT202400436T1/it unknown
- 2019-01-16 SG SG11202101117QA patent/SG11202101117QA/en unknown
- 2019-01-16 EP EP23202199.8A patent/EP4282472A3/en active Pending
- 2019-01-16 PT PT197035140T patent/PT3840753T/pt unknown
- 2019-01-16 HR HRP20241454TT patent/HRP20241454T1/hr unknown
- 2019-01-16 KR KR1020217008263A patent/KR20210046729A/ko active Pending
- 2019-01-16 EP EP23202200.4A patent/EP4285990A3/en active Pending
- 2019-01-16 EP EP23202198.0A patent/EP4289476A3/en not_active Withdrawn
- 2019-01-16 RS RS20241181A patent/RS66094B1/sr unknown
- 2019-01-16 EP EP23202201.2A patent/EP4285991A3/en not_active Withdrawn
- 2019-01-16 SI SI201930852T patent/SI3840753T1/sl unknown
- 2019-01-16 MX MX2021002070A patent/MX2021002070A/es unknown
- 2019-01-16 EP EP23202183.2A patent/EP4289475A3/en active Pending
- 2019-01-16 ES ES19703514T patent/ES2993833T3/es active Active
-
2021
- 2021-02-18 IL IL280961A patent/IL280961B1/en unknown
- 2021-02-19 MX MX2024008350A patent/MX2024008350A/es unknown
- 2021-02-19 CL CL2021000435A patent/CL2021000435A1/es unknown
-
2023
- 2023-04-25 JP JP2023071652A patent/JP7784398B2/ja active Active
- 2023-10-02 US US18/479,396 patent/US20240277687A1/en active Pending
-
2024
- 2024-03-13 CL CL2024000741A patent/CL2024000741A1/es unknown
- 2024-03-13 CL CL2024000739A patent/CL2024000739A1/es unknown
-
2025
- 2025-07-04 AU AU2025205141A patent/AU2025205141A1/en active Pending
- 2025-07-14 JP JP2025117816A patent/JP2025165955A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241454T1 (hr) | Migalastat za upotrebu u postupcima liječenja fabrijeve bolesti kod pacijenata koji imaju mutaciju u gla genu | |
| Loubser et al. | Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury | |
| JP2007528352A (ja) | 洞炎に関連する慢性の顔面痛および頭痛のボツリヌス毒素での治療 | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| Kukushkin et al. | Results of a randomized double blind parallel study on the efficacy and safety of tolpersione in patients with acute nonspecific low back pain | |
| HRP20020234A2 (en) | Use of retigabin for treating neuropathic pain | |
| IL272893B1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| JP2013540826A5 (enExample) | ||
| HRP20240025T1 (hr) | Liječenje bolesnika s klasičnom fabrijevom bolešću migalastatom | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| Barbour et al. | Emergency physician resistance to a take-home naloxone program led by community harm reductionists | |
| Lotfabadi et al. | Liquid nitrogen cryotherapy versus 70% trichloroacetic acid in the treatment of anogenital warts: a randomized controlled trial | |
| HRP20250179T1 (hr) | Postupci liječenja fabrijeve bolesti kod pacijenta s mutacijom gla gena | |
| JP2016505050A5 (enExample) | ||
| HRP20211661T1 (hr) | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| CN102813924B (zh) | 一种基于青藤碱的用于镇痛的药物组合产品 | |
| CN101366726A (zh) | 一种治疗皮肤疾病的药物组合物 | |
| FI4327869T3 (fi) | Menetelmiä fabry-potilaiden hoitamiseksi, joilla on munuaisen vajaatoiminta | |
| Chaplin | Dupilumab for the treatment of atopic dermatitis | |
| CN103494839B (zh) | 一种用于治疗膝盖转筋的中药组合物 | |
| CN109999179A (zh) | 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用 | |
| Zhu | Clinical study on acupuncture in treating perimenopausal insomnia | |
| MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. |